Mitochondrial Peptide MOTS-c Prevents Pancreatic Cell Aging to Delay Diabetes
Background
Mitochondria are vital organelles, crucial for cell survival and function, partly through unique peptides encoded by their own genome. While mitochondrial dysfunction is a known hallmark of age-related diseases and cellular senescence (the process of cells losing their ability to divide and function), the precise role of these mitochondrial-encoded peptides in pancreatic β-cell senescence during type 1 and type 2 diabetes pathogenesis has been largely unexplored. This study specifically addresses how the mitochondrial-encoded peptide MOTS-c influences pancreatic islet cell senescence and its potential impact on diabetes progression.
Results
The study revealed that MOTS-c levels significantly decrease with aging and senescence in pancreatic islet cells. Treatment of aged C57BL/6 mouse pancreatic islets with MOTS-c successfully reduced pancreatic islet senescence by modulating nuclear gene expression and metabolites involved in β-cell senescence. In animal models, MOTS-c treatment improved pancreatic islet senescence and glucose intolerance in both S961-treated C57BL/6 mice and nonobese diabetic (NOD) mice. The most significant finding is that MOTS-c effectively prevents pancreatic islet cell senescence and delays the progression of diabetes in multiple mouse models. Furthermore, human data showed that circulating MOTS-c levels are notably lower in type 2 diabetes patients compared to healthy controls, suggesting a direct clinical relevance.
Why It Matters
These findings are highly significant as they identify MOTS-c as a critical regulator of pancreatic islet cell senescence, a process implicated in both type 1 and type 2 diabetes. The ability of MOTS-c to reduce senescence and improve glucose intolerance suggests its potential as a novel senotherapeutic agent (a therapy targeting senescent cells). This research could pave the way for developing new therapeutic strategies to prevent pancreatic islet cell dysfunction and delay diabetes progression in humans. Future steps would involve more detailed preclinical studies, including dose-response analyses and long-term safety, potentially leading to human clinical trials (e.g., Phase II) to confirm efficacy and safety.